Anyone who has ever woken up with that familiar, unwelcome tingle on their lip knows the drill: a frantic search for the tube of cream, the sticky residue on your fingers, and the ritual of reapplying every few hours for days. For the roughly 80 percent of Swedish adults who carry the herpes simplex virus, cold sores are not just a nuisance—they are a recurring, inconvenient reality. But a new over-the-counter treatment launched in Sweden this May is turning that routine on its head.
Navamedic, a Norwegian healthcare company, has introduced Virono, a single-dose tablet you stick to your gum at the very first sign of a flare-up. It is the first OTC cold sore treatment of its kind, and it signals a quiet shift in how we think about self-care for viral infections.
From Prescription to Pharmacy Shelf
Virono belongs to a category known as an “Rx-to-OTC switch”—a medicine that was once available only by prescription but has now been proven safe enough for people to use on their own. The active ingredient, aciclovir, is a well-known antiviral that has been used for decades to treat herpes infections. What makes Virono different is its delivery system. Instead of swallowing a pill that travels through your entire body, or dabbing a cream on the surface of your skin, you place a small, sticky tablet against your cheek. It slowly releases the drug directly onto the affected area over several hours, with just one application needed for the entire outbreak.
This mucoadhesive buccal technology (the clinical term for “sticky tablet that goes in your mouth”) is patented by the Swedish company Lauriad. It turns a multiple-times-a-day chore into a single, hands-off step.
The Numbers Behind the Nuisance
While cold sores are rarely dangerous, they are remarkably common. In Sweden alone, roughly one million people experience at least three outbreaks every year. The combined OTC cold sore market in Sweden, Finland, and the Netherlands is valued at around NOK 70 million at the wholesale level. That may seem small compared to blockbuster drugs for chronic conditions, but it represents a steady, predictable consumer demand. People do not stop getting cold sores because of a pandemic or an economic downturn—it is a perennial problem.
Navamedic is betting that convenience will be the differentiator. “This launch is a good example of how Rx-to-OTC switches can expand access to clinically proven treatments,” says Karianne Femtehjell Olsen, Commercial Director for Consumer Health & Nutrition at Navamedic. “We are pleased to bring this to the Nordic market and look forward to making it available to a broader consumer base across our markets.”
A Second Opinion on Self-Medication
Not everyone is unreservedly enthusiastic about the shift from prescription to pharmacy shelf. Some virologists point out that while aciclovir is effective, self-diagnosis can be tricky. A person’s first cold sore can look like a bacterial infection or even a severe allergic reaction. Others worry that easy access to antivirals could lead to overuse, potentially contributing to antiviral resistance, though that risk is considered low with topical and local treatments. Still, for the millions of people who have been managing this condition for years and know their triggers inside out, the new option feels liberating.
What This Means for the Pharmacy Aisle
The launch of Virono is also a strategic move for Navamedic. The company has been quietly building its Consumer Health division, aiming to offer more differentiated self-care products across the Nordics, the Baltics, and the Benelux region. A single-dose OTC antiviral tablet fits neatly into that portfolio. It is a premium product—more sophisticated than a tube of cream—and it commands a higher price point, which is good for margins. For consumers, the trade-off is simple: spend a little more for a lot less hassle.
The rollout begins in Swedish pharmacies this month. Finland is next, and the Netherlands is expected to follow later in 2026. For anyone who has ever paused awkwardly before a date or a business meeting, wondering if that little red spot is about to explode, the timing could not be better.
